GeoVax Labs, Inc. New GOVX
Analyst Ratings
- Consensus
- Moderate Buy — 1 Buy · 1 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $5.50 (+1462.5% upside)
Key Stats
- Today's Range
- $0.34 – $0.36
- 50-Day Range
- $0.34 – $1.02
- 52-Week Range
- $0.34 – $20.00
- Volume
- 284K shs
- Average Volume
- 956K shs
- Market Cap
- $3.14 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.99%
- Days to Cover
- 1.00
About GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Related Stocks
Compare head-to-head: GOVX vs LLY·GOVX vs JNJ·GOVX vs ABBV·GOVX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.